AR094346A1 - Derivados de azaindol como inhibidores de las proteína quinasas - Google Patents

Derivados de azaindol como inhibidores de las proteína quinasas

Info

Publication number
AR094346A1
AR094346A1 ARP140100010A ARP140100010A AR094346A1 AR 094346 A1 AR094346 A1 AR 094346A1 AR P140100010 A ARP140100010 A AR P140100010A AR P140100010 A ARP140100010 A AR P140100010A AR 094346 A1 AR094346 A1 AR 094346A1
Authority
AR
Argentina
Prior art keywords
hnc
group
alkyl
halogen
ch2nhc
Prior art date
Application number
ARP140100010A
Other languages
English (en)
Original Assignee
Oribase Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47989197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR094346(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oribase Pharma filed Critical Oribase Pharma
Publication of AR094346A1 publication Critical patent/AR094346A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)

Abstract

Preparación de los compuestos de la fórmula (1), sus usos, en particular en la inhibición de las proteínas quinasas que están implicadas, por ejemplo, en numerosas enfermedades tales como cánceres o trastornos del sistema inmune. Reivindicación 1: Un compuesto de la fórmula (1) que se caracteriza por el hecho de que, R¹ es un grupo alquilo C₁₋₆, preferentemente metilo, etilo o n-propilo; X es CH₂ o C=O; R² es un átomo de hidrógeno, un grupo alquilo o un átomo de halógeno; Y es elegido de un grupo que consiste en HNC(O), HNC(S), HNSO₂, HNC(O)CH₂, HNC(O)NH, HNC(S)NH, C(O)NH, C(O)NHCH₂, CH₂NHC(O) y CH₂NHC(S); y R³ es elegido de un grupo que consiste en: un grupo fenilo mono o polisustituido con: un hidroxilo, un halógeno, alquilo C₁₋₆, preferentemente una alquil C₁₋₆-amina secundaria, un alcoxi C₁₋₆, un trifluoroalcoxi C₁₋₆, preferentemente un trifluorometoxi, un alquilo C₁₋₆, preferentemente un metilo, isopropilo, un trifluoroalquilo C₁₋₆, preferentemente un trifluorometilo, un fragmento heteroarilo opcionalmente sustituido con un alquilo C₁₋₆, un trifluoroalquilo C₁₋₆, un halógeno y/o un hidroxilo, donde dicho fragmento heteroarilo es elegido de un grupo que consiste en dihidrobenzofurano, indol, benzodioxol, benzotriazol, piridina o un tiazol preferentemente monosustituido con un metilo, un imidazol con la condición de que Y sea HNC(S), HNSO₂, HNC(O)CH₂, HNC(O)NH, HNC(S)NH, C(O)NHCH₂, CH₂NHC(O), CH₂NHC(S) o C(O)NH donde NH está directamente ligado a R³, preferentemente Y es HNC(S); un grupo heteroarilo preferentemente elegido de un grupo que consiste en dihidrobenzofurano, indol, benzodioxol, benzotriazol, piridina, opcionalmente sustituido con un alquilo C₁₋₆, un trifluoroalquilo C₁₋₆, un halógeno y/o un hidroxilo; un grupo cíclico monosustituido no aromático, preferentemente un alquilo C₃₋₁₀ cíclico, monosustituido con un hidroxilo, un halógeno, alquilo C₁₋₆, un alcoxi C₁₋₆, un trifluoroalcoxi C₁₋₆, un alquilo C₁₋₆, un trifluoroalquilo C₁₋₆; y un fragmento que es elegido de un grupo que consiste en: el grupo de formulas (2); y/o las sales de adición farmacéuticamente aceptables, solvatos, enantiómeros, diastereoisómeros de los mismos, como así también mezclas de los mismos.
ARP140100010A 2012-12-28 2014-01-03 Derivados de azaindol como inhibidores de las proteína quinasas AR094346A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1262934A FR3000494B1 (fr) 2012-12-28 2012-12-28 Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases

Publications (1)

Publication Number Publication Date
AR094346A1 true AR094346A1 (es) 2015-07-29

Family

ID=47989197

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100010A AR094346A1 (es) 2012-12-28 2014-01-03 Derivados de azaindol como inhibidores de las proteína quinasas

Country Status (16)

Country Link
US (1) US9493455B2 (es)
EP (1) EP2938613A1 (es)
JP (1) JP2016507509A (es)
KR (1) KR20150108372A (es)
CN (1) CN105008355B (es)
AR (1) AR094346A1 (es)
AU (1) AU2013369243A1 (es)
BR (1) BR112015015653A8 (es)
CA (1) CA2896822A1 (es)
CL (1) CL2015001818A1 (es)
FR (1) FR3000494B1 (es)
HK (1) HK1215578A1 (es)
IL (1) IL239628A0 (es)
RU (1) RU2015128606A (es)
TW (1) TW201431858A (es)
WO (1) WO2014102378A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101852169B1 (ko) 2010-05-20 2018-04-26 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
KR20160134865A (ko) * 2014-04-14 2016-11-23 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용
CN107820495A (zh) * 2015-04-29 2018-03-20 桑福德-伯纳姆医学研究院 靶向epha4的配体结合域的新型epha4抑制剂
SI3322706T1 (sl) 2015-07-16 2021-04-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
CN107663151B (zh) * 2016-07-28 2021-11-26 江苏豪森药业集团有限公司 甲磺酸氟马替尼的中间体合成方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
SG11201908569QA (en) 2017-03-21 2019-10-30 Arbutus Biopharma Corp Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
KR101990054B1 (ko) * 2017-04-25 2019-06-17 대구대학교 산학협력단 로손을 유효성분으로 포함하는 항암 조성물
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
KR102319676B1 (ko) * 2019-11-14 2021-11-02 한국과학기술연구원 피롤로피리미딘, 피롤로피리딘, 인다졸 화합물 유도체 및 이를 포함하는 치료용 약학 조성물
CN114805120A (zh) * 2022-05-23 2022-07-29 江苏瑞达环保科技有限公司 一种间氰甲基苯甲酸甲酯的合成工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
CN101208338B (zh) 2005-07-29 2010-12-29 霍夫曼-拉罗奇有限公司 氮杂苯并咪唑衍生物，它们的制备以及作为抗癌剂的应用
BRPI0716477A2 (pt) * 2006-09-06 2014-03-18 Hoffmann La Roche Derivados heteroarila como inibidores de quinase protéica
WO2008144253A1 (en) * 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101808994B (zh) * 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
JP2011513330A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
FR2941948B1 (fr) * 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
AU2010343102B2 (en) * 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
FR3000492B1 (fr) * 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases

Also Published As

Publication number Publication date
FR3000494B1 (fr) 2015-08-21
CN105008355A (zh) 2015-10-28
CN105008355B (zh) 2017-08-04
TW201431858A (zh) 2014-08-16
EP2938613A1 (en) 2015-11-04
RU2015128606A (ru) 2017-02-02
BR112015015653A8 (pt) 2018-01-23
US9493455B2 (en) 2016-11-15
KR20150108372A (ko) 2015-09-25
US20150353540A1 (en) 2015-12-10
HK1215578A1 (zh) 2016-09-02
JP2016507509A (ja) 2016-03-10
IL239628A0 (en) 2015-08-31
WO2014102378A1 (en) 2014-07-03
FR3000494A1 (fr) 2014-07-04
CA2896822A1 (en) 2014-07-03
BR112015015653A2 (pt) 2017-07-11
CL2015001818A1 (es) 2015-10-02
AU2013369243A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
AR094346A1 (es) Derivados de azaindol como inhibidores de las proteína quinasas
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
EA201691302A1 (ru) Новые гетероциклические соединения
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
EA201000113A1 (ru) Пиразольные соединения
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
AR067886A1 (es) Derivados de acido azabifenilaminobenzoico
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
EA201290260A1 (ru) Бензимидазол-имидазольные производные
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
AR098522A1 (es) Compuesto de triazolo-piridina
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR093035A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR094797A1 (es) Derivados de pirrolotriazina como inhibidores de pi3k

Legal Events

Date Code Title Description
FB Suspension of granting procedure